Stay updated on Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedA new revision tag v3.5.4 was added, replacing the previous v3.5.3; this indicates an internal software or content-management update rather than a substantive change to the study information.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check31 days agoChange Detected<div>Updates the page’s revision/version label from <code>v3.5.2</code> to <code>v3.5.3</code>.</div>SummaryDifference0.1%

- Check38 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check59 days agoChange DetectedNo substantive changes detected in core content; study details, eligibility criteria, and outcome measures appear unchanged.SummaryDifference0.1%

- Check66 days agoChange DetectedRevision updated to v3.5.0, replacing v3.4.3; no study content or user functionality is affected.SummaryDifference0.1%

- Check74 days agoChange Detected- Revision tag updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.